A természetes progeszteron kutatása 1976-ra datálható, melyet egy norvég származású amerikai orvos, nevezetesen Dr. Lee, MD kezdeményezett.
Dr. Lee-nek és a mögötte álló nemzetközi orvos-csoportnak köszönhetően a következő tudományos tanulmányok, állati és klinikai kísérletek igazolják a természetes progeszteron hatékonyságát:
Goodman, Lousi S., and Alfred Gilman: The Pharmacological Basis of Therapeutics, 8th edition. Toronto, The Macmillan Company, 1990: Chapter 58.
Kolata, Gina. Hormone replacement study a shock to the medical system. New York Times, July 10, 2002
Premarin Statistics: Business Week Online: September 27, 2002
Textbook of Clinical Chemistry. Norbert W. Tietz. PhD., ed. Philadelphia: W.B. Saunders Co., 1986: 1085-1171
Thomas, J. Hywel, and Brian Gillham. Will’s Biochemical Basis od Medicine, 2nd Edition. Oxford: Butterworth-Heinemann Ltd., 1989: Chapter 17.
Goodman, Lousi S., and Alfred Gilman: The Pharmacological Basis of Therapeutics, 8th edition. Toronto, The Macmillan Company, 1990: Chapter 58.
Morley, John E., M.B.., 1994. Nutrition modulation of behavior and immunocompetence. Nutrition Reviews August, 52 (8): S6-S8
Textbook of Clinical Chemistry. Norbert W. Tietz, PhD., ed. Philadelphia: W.B. Saunders Co., 1986: 1085-1171
Will’s Biochemical Basis of Medicine, 2nd edition. Oxford: Butterworth- Heinemann Ltd., 1989: Chapter 17.
Albright, F. 1936. Studies in ovarian function III: The menopause. Endocrinology 20:24
Barret-Conner, E. 1991. Postmenopausal estrogen and prevention bias. Annals of Internal Medicine 115:455-56.
Byyny, R.L., and L. Speroff. A Clinical Guide for the care of Older Women. Baltimore: Williams & Wilkins, 1990
Coney, Sandra. The menopause Industry. Alameda, Calif.: Hunter House, 1994.
Coronary Drug Project Research Group. 1973 Coronary drug project: Findings leading to the discontinuation of the 2.5 mg/day estrogen group. Journal of American medical Association (hereafter cited as JAMA) 226:652-57
1978 Coronary Drug Project: estrogens and cancer (letter). JAMA 239:2758-59
Gallagher, J.C., W.T. Kable, and D. Goldgar. 1991. The effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. American Journal of Medicine 90: 171-78
Jaszman. I., N.D. Van Lith, and J.C. Saat. 1969. The perimenopausal symptoms: The statistical analysis of a survey. Parts A and B. Medical Gynecology Sociology 4: 268-76
Jayo, M.J., D.S. Weaver, M. R. Adams, and S.E. Rankin. 1990. Effects on bone of surgical menopause and estrogen therapy with or without progestreone replacement in cynomolgus monkeys. American Journal of Obstetrics and gynecology 614:618
Kaufert, P.A., P.. Gilbert, and R. Tate. 1987. Defining menopausal status: The impact of longitudinal data. Maturitas 9:217-26
Lacey, J. V., P.J.Mink, J.H. Lublin, et al. Menopausal hormone replacement and risk of ovarian cancer. JAMA, July 17, 2002. vol. 288, no.3.
Leather, A.T., M. Savras, and J.W.Stuidd. 1991. Endometrial histology and bleeding patterns after eight years of continuous combined estrogen and progestin therapy in postmenopausal women. Obstet Gynecol 78:1008-10.
Mc Kinlay, S.M., D.J. Brambilla, and J.G.Posner. 1992. The normal menopausal transition. Maturitas 14:103-15.
Neugarten, B.L., and R. J. Kraines. 1964. Menopausal symptoms in women of various ages. Psychom Med 27-266-73.
Prior, J.C. One Voice on Menopause. JAMWA 49, no.1. (Jan6Feb 1994):27-29 1990. Progesterone as a bone-trophic hormone. Endocr Rev 11:386-98.
1991 Postmenopausal estrogen therapy and cardiovascular disease (letter). New England Journal of medicine 326:705-706.
Prior, J.C., B.. Ho Yuen, P. Clement, et al. 1992. Reversible luteal phase changes and infertility associated with marathon training. Lancet 1:269-270.
Prior, J.C., and Y.M. Vigna. 1991. Ovulation disturbances and exercise training. Clin Obstet Gynecol 26:180-190.
Prior, J.C., and Y.M. Vigna, M. Alojado, et al. 1987. Conditioning exercise decreases premenstrual symptoms: A prospective controlled six-months trial. FertilSteril 47:402-406.
Prior, J.C., and Y.M. Vigna, M.T. Schechter, and A.E.Burgess. 1990. Spinal bone loss and ovulatory disturbances. New England Journal of Medicine 323:1221-27.
Reyes, F.L., J.S. Winter, and C. Paiman. 1977. Pituitary ovarian relationships preceding the menopause: a cross-sectional study of serum follicle-stimulating hormone, lutenizing hormone, prolactin, estradiol and progesterone levels.
American Journal of Obstetrics and Gynecology 129:557-64.
Rinzler, Carol Ann. Estrogen and Breast Cancer. New York: MacMillan Publishing Co., 1993:31-32.
Seaman, Barbara, and Gideon Seaman. Women and the Crisis in Sex Hormones. New York: Rawson Associates, 1977:82.
Sherman, B. M., J.H. West, and S.G. Korenmam. 1976. The menopausal transition: Analysis of LH, FSH, estradiol and progesterone concentrations during
Strauss, S., 1988. A capsulated history of drug law in the U.S. US Pharmacist. November.
Tilt, E.J. The Change of Life in Health and Disease. A Practical Treatise on the Nervous and Other Affections Incidental to Women at the Decline of Life.
Philadelphia: Lindsay and Blakiston, 1871.
Trial of HRT to prevent CHD halted early because of increased harm. Lancet, July 13, 2002, vol. 360, no. 9327.
Vaughn, Paul. The Pill on Trial. London: Weidenfeld and Nicolson, 1970:25,
Writing Group for the Women’s health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, July 17, 2002, vol. 288, no.3.
Campbell, B.C., and P.T. Ellison. 1992. Menstrual variation in salivary testosterone among regularly cycling women. Horm Res 37:132-136.
DeMarco, Carolyn, MD. Take Charge of Your Body. Winlaw, BC, V0G 2J0, Canada: The Well Woman press, P.O. Box 66, 1994.
Documenta Geigy. Scientific Tables. 6th Edition. Ardsley, NY: geigy Pharmaceuticals: 493.
Ellison, P.T., C. Panter-Brick, S.F. Lipson, and M.T. O’Rourke. 1993. The ecological context of human ovarian function. Human Reproduction 8:2248-58.
Greer, Germaine. The Change: Women, Aging and menopause. New York: Fawcett Columbine, 1991.
Hammar, M.L., M.B. Hammar-Henriksson, et al. Few oligoamenorrheic athletes have vasomorot symptoms. Maturitas 2000 Mar 31, 34(3): 219-25.
Human Reproduction, December 1993.
Ivarsson, T., A.C. Spetz, and M. Hammar. Physical exercise and vasomotor
Lennon, H. M., H.H. Wotiz, L. Parsons, and P.J. Mozden. 1966. reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA 196:112-20.
Leonetti, H.B., S. Londo, and JN Anasti. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstetrics and Gynecology 94 (1999): 225-228.
Lipsett, M.P. Steroid hormones, in reproductive Endocrinology, Physiology, and Clinical management. S.S. C. Yen, and R. B. Jaffe, eds. Philadelphia: W.B. Saunders Co., 1978:80.
Novak’s textbook og Gynecology, 11th edition. Baltimore: Williams & Wilkins, 1987.
Overlie, I., M.H. Moen, A. Holte, and A. Finset, Androgens and estrogens in relation to hot flushes durring the menopausal transition. Maturitas 2002 Jan 30: 41 (1): 69-77.
Raloff, J. 1993. Ecocancers. Science news, July 3, 144:10-13 and reported in article Sperm-count drop tied to pollution rise. Medical Tribune, March 26, 1992.
Raz, R., and W.E. Stamm. 1993. A controlled trial of intra-vaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine 329:753-56-
Rose, D.P. Obstetrics and gynecology, 1977. Vines, Gail. Oestrogen overdose. British Vogue.
Yahya, S., and N. Rehan. Age, pattern and symptoms of menopause among rural women of Lahore. J Ayub Med Coll Abbottabad 2002 Jul-Sep, 4(3): 9-12.
Zhao, G., and L. Wang. Menopausal symptoms: experience of Chinese women. Climacteric 2000 Jun, 3(2): 135-44.
Baj, Z. et al. The effect of chronic exposure to formaldehyde, phenol and organic clorohydrocarbons on peripheral blood cells, and the immune system in humans.
Begley, S., and D. Glick. 1994. The estrogen complex. Newsweek, March 21: 76- 77.
Colborn, T., F.S. vom Saal, and A. M. Soto. 1993. Developmental effects of endocrine-disrupting chemicals in wild-life and humans. Environmental Health perspectives 10:378-84.
Cone, Marla. 1994. Sexual confusion in the wild. Pollution’s effect on sexual development fires debate. Battle looms on chemicals that disrupt hormones. 3- part series. The Los Angeles Times. October 2-4.
Faustini, A., et al. Immunological changes among farmers exposed to phenoxy herbicides: preliminary observations. Occup Environ med 1996 Sep., 53(9):583- 85.
Fitzgerald, E.F. et al. Polychlorinated biphenyl (PCB) and dichlorodiphenyl dichloroethylene (DDE) exposure among Native American Men from contaminated Great Lakes fish and wildlife. Toxicol Ind helath 1996 May-Aug, 12(3-4): 361-68.
Hagmar, L., et. Al. High consumption of fatty fish from Baltic Sea is associated with changes in human lymphocyte subset levels. Toxicol lett 1995 May, 77(1-3): 335-42.
Hileman, beth. 1994. Reproductive estrogens linked to reproductive abnormalities, cancer. Chemical and Engineering News January 31:19-23.
Hoy, Claire. The Truth About Breast Cancer. Stoddard, 1995.
Lemonick, Michael D. 1994. Not so fertile ground. Time September 19:68-70.
McLachlan, John. Diagram “Hormonal mimic” taken from 1993. Functional toxicology: A new approach to detect biologically active xeno-biotics.
Environmental Health Perspectives 10:386-78.
Nagayama, J. et al. Postnatal exposure to chlorinated dioxins and related chemicals on lymphocyte subsets in Japanese breastfed infants. Chemosphere 1998 Oct-Nov, 37 (9-12): 1781-87
Raloff J. 1993. Ecocancers. Science News 144, July 3:10-13.1994
That feminine touch. Science News 145, Jan 22:56-59.
Roof, R.L. gender influences outcomes of brain injury. Progesterone plays a protective role. Brain Research 1993, April 2, 607(1-2): 333-36.
Ross, P.S. et al Impaired cellular immune response in rats exposed perinatally to Baltic Sea herring oil or 2,3,7,8-TCDD. Arch Toxicol 1997, 71(9): 563-74.
Svenssonm B.G., et al. Parameters pf immunological competence in subjects with high consumption of fish contaminated with persistent organochlorine compounds. Int Arch Occup Environ hea1lth 1994, 65(6):351-58.
Van Loveren, H., et al. Contaminant-induced immunosuppression and mass mortalities among harbor seals. Toxicol Lett 2000 Mar 15, 112-113:319-24.
Weiss, Rick. 1994. Estrogen in the environment. The Washington Post, January 25: 10-13.
Campbell, B.C. and P.T. Ellison. 1992. menstrual variation in salivary testosterone among regularly cycling women. Horm Res 37:132-36.
DeBold, J.F., and C.A. Frye. 1994. Progesterone and the neural mechanisms of hamster sexual behavior. Psychoneuroendocrinology 19:563-66.
Elks, M.L., 1993. Peripheral effects of sex steroids implications for patient management. JAMWA 48:41-45.
Goodman, Louis S., and Alfred Gilman. The Pharmacological Basis of Therapeutics, 8th edition. Toronto: The Macmillan Company, 1990: chapter 58. History of progesterone as described by Goodman and Gilman. The Pharmacological basis of Therapeutics, 6th edition, 1980.: chapter 61 (Estrogens and progestins: 1420), and Textbook of clinical chemistry. Norbert W. Tietz, PhD., ed. Philadelphia. W.B. Saunders Co., 1986: 1085-1171.
Roof, Robin, et al. of Rutgers University. 1993. reported in The Economist, December 11, 329:35.
Stampfer, M.J., G.A. Colditz, W.C. Willett, et al. 1991. Postmenopausal estrogen therapy and cardiovascular disease-Ten year follow-up from Nurses’ Questionnaire Staudy. New England Journal of Medicine 325:756-62.
Swerdloff, R.S. and C. Wang. 1993. Androgen deficiency and aging in men. WJM 159:579-84.
Textbook of Clinical Chemistry. Norbert W. Tietz, PhD. Ed, Philadelphia: W.B. Saunders Co., 1986:1085-1171.
Thomas, J. Hywel, and Brian Gillham. Will’s Biochemicol Basis of Medicine, 2nd edition. Oxford:Butterworth-Heinemann Ltd., 1989: chapter 17.
Witt, D.M., L.J. Young, and D. Crews. 1994. Progesterone and sexual behavior in males. Psychoneuroendocrinology 19:553-56.
Bergkvist, L., H.-O. Adami I. Persson, R. Hoover, and C. Schairer. 1989. The risk of breast cancer after estrogen and estrogen-progestin replacement. New Englend Journal of medicine 321:293-97.
Crane, M.G., and J.J.. Harris. Effects of gonadal hormones on plasma rennin activity and aldosterone excretion rate. In ?etabolic Effects of Gonadal Hormones and Contraceptive Steroids, H.A. Salhaninck, D.M. Kipnis, and R.L. Vande Weile, eds.
New York: Plenum Press, 1969:446-46, and discussion: 736.
Crane, M.G., J.J. Harris, and W. Winsor III. 1971. Hypertension, oral contraceptive agents, and conjugated estrogens. Annals of Internal Medicine 74:13-21.
Edgren, R.A. Progestagens. Reprinted from Clinical Use of Sex Steroids. Chicago: Year Book medical Publishers, Inc., 1980.
Gambrell, R.D. 1982. The menopause: benefits and risks of estrogen- progesterone replacement therapy. Fertile Steril 37:457-74.
Hargrove, J.T., W.S. Maxson, A. C. Wentz, and L.S. Burnett. 1989. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol
Landau, R.L. and K. Luigibihl. 1961. The catabolic and natriuretic effects of progesterone in man. Recent progress in Hormone Reasearch 17:249-81.
Medical Times. 1989. Sept:35-43.
Ottoson, U.B., B.G. Johansson, and B. von Schoultz. 1985. Subfractions of high- density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. American Journal of Obstetrics and Gynecology 151:746-50.
Scientific American Medicine, updated 1992. New York: Scientific American, chapter 15 (x):9.
Stevenson, J.C., K.F. Ganger, et al. 1990. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 336:265-69.
Whitehead, M.I., D. Fraser, L. Schenkel, D. Crook, and J.C. Stevenson. 1990. transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet 335:310-12.
The Writing Group for the PEPI Trial, 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestins interventions (PEPI) trial. JAMA, January 18. 273(3): 240-241.1995
Backstrom, T., 1962. Epileptic seizures in women related to plasma oestrogen and progesterone during the menstrual cycle. Acta neurol Scand 54:312-47.
Backstrom, T. et al. 1974. estrogen and progesterone in plasma in relation to premenstrual tension. J Steroid Biochem Mol Biol 5:257-60.
Backstrom, T. et al. Effects of ovarian steroid hormones on brain excitability and their relation to epilepsy seizure variation during the menstrual cycle. Advances in Epileptology, XVth Epilepsy International Symposium, New York, raven Press,
Braverman, Eric. 1993. New era in hormone therapy. Total Helth 7, no. 4 (August): 31.1991
natural estrogen and progesterone research indicates health benefits of natural vs. synthetic hormones. Total Health 13, no. 5(October): 55.
Gonzalez, Deniselle M.C., et al. 2002. basis of progesterone protection in spinal cord neurodegeneration. J Steroid Biochem Mol Biol Dec, 83 (1-5): 199-209.
Harris, Brian. 1994. Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II, Wales. British Medical Journal, April 19, 308:949-53.
Leary, Warren E. 1995. progesterone may play a major role in the prevention of nerve disease. New York Times, June 27, C3.
Peat, Ray, PhD. Progesterone in Orthomolecular medicine. Self-published.
Roof, R.L., et al. 1993. Gender influences outcome of brain injury: Progesterone plays a protective role. Brain Res. April 2, 607 (1-2):333-36.1994
Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol, September, 129(1): 64-69.
The Biologic Role of Dehydroepiandrosterone. M. Kalimi and W. regelson, ed. Walter de Gruyter, 1990.
Ebeling, P., and V.A. Koivisto. 1994. Physiological importance of dehydroepiandrosterone. Lancet 343:1479-81.
Greenblatt, R.B. 1987. The use of androgens in the menopause and other gynetic disorders. Obstet Gynecol Clin North Am.Mar, 14(1): 251-68.
Lissoni, P., et al. 1998. Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: Selective deficiency in metastatic disease. Int
Campbell, B.C., and P.T. Ellison. 1992. Menstrual variation in salivary testosterone among regularly cycling women. Horm Res 37:132-36.
Kaplan, Abraham, MD, The nervous system, Volume I., The Hypothalamus Supplement. Illustrated by Frank H. Netter, MD. New York: CIBA, 1957:147-65
A good presentation of the functions and neural systems of the limbic brain.)
Prior, J.C., Y.M. Vigna, M.T. Schechter, et al. 1990. Spinal bone loss and ovulatory disturbances. New Englend Journal of Medicine 323:1221-27.
Stevenson, J.C., K.F. Ganger, et al. 1990. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet, 336:265-69.
Arafat, E.S., and J.T. Hargrove. 1988. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. American Journal of Obstetrics and Gynecology, 159:1203-1209
Belchetz, P.E. 1994. Hormonal treatment of postmenopausal women. New England Journal of Medicine 330:1062-71.
Lees, B., T. Molleson, T.R.Arnett, and J.C. Stevenson, 1993. Differences in proximal femur bone density over two centuries. Lancet 341:673-75.
Leridon, H. Human fertility: The Basic Components. Chicago: University of Chicago Press, 1977:202.
Textbook of Clinical Chemistry. Philadelphia: W.B. Saunders Co., 1986:1088.
Van Noord-Zaadstra, B.M., C. W. N. Looman, H. Alsback, et al. 1991. Delaying childbearing: Effects of age on fecundity and outcome of pregnancy. British Medical Journal 302:1361.65.
Velde, E.R. 1993. Disappearing ovarian follicles and reproductive aging (letter).
Bower, B. 1998. Stress hormones may speed up brain aging. Science News, vol. 153, no. 17-263.
Albright, F., P.H. Smith, and A.M. Richardson. 1941. Postmenopausal osteoporosis: Its clinical features. JAMA 116:2465-74.
Aitken M., D.M. Hart and R. Lindsay. 1973. Oestrogen replacement therapy for prevention of osteoporosis after oopherectomy. British Medical Journal 3:515-18.
Barengolts, E.I., D.J. Curry, et al. 1991. Comparison of the effects of progesterone and estrogen on established bone loss in ovariectomized aged rats. Cells and Materials supplement 1 (pages 105-111).
Barengolts, E.I, H.F. gajardo, et al. 1990. Effects of progesterone on post- ovariectomy bone loss in aged rats. Journal of Bone Mineral Res 5:1143-1147.
Barzel, U.S., 1988. Estrogens in the prevention and treatment od postmenopausal osteoporosis: a review. American Journal of Medicine 85:847-50.
Bayley, T.A., et al. 1990. Fluoride-induced fractures: relation to osteogenic effects. Journal of Bone Mineral Res Mar, 5 Suppl 1:S217-22.
Bone, H.G. et al. 2000. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J. Clin Endocrinol Metab Feb, 85(2):720- 26.
Christiansen, C., M.S. Christiansen, and I. Transbol. 1981. Bone mass in postmenopausal women after withdrawal of oestrogen/progestagen replacement therapy. Lancet February 28:459-61.
Coats, C. 1990. Negative effects of a high-protein diet. Family Practice Recertification 12:80-88.
Cooper, C., C.A.C. Wickham, D.J.R. barker, and S.J. Jacobsen. 1991. Water
Cummings, S.R., W.S. Browner, D. Bauer, K. Stone, et al- 1998. Endogenous hormones and the risk of hip and vertebral fracture among older women. NEJM 339:733-38.
Cummings, S.R., M.C. Nevitt, W.S. Browner, et al. 1995. Risk factors for hip fracture in white women. New England Journal of Medicine 332:767-73.
Cundy, T., M. Evans, H. Roberts, et al. 1991. Bone density in women receiving a depot medroxyprogesterone acetate for contraception. British medical Journal 303:13-16.
Dalsky, G.P., K.S. Stocke, A.A. Ehsani, et al. 1988. Weight-bearing exercise training and femoral neck and lumbar spine bone mineral density. Annals of Internal Medicine 108:824-28.
Danielson, C., J.L. Lyon, M.Egger, and G.K. Goodenough. 1992. Hip fractures and fluoridation in Utah’s elderly population. JAMA 268:746-47.
Delmas, P.D., K.E. Ensrud, et al. 2002. Efficiacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomizes clinical trial. Journal of Clinical Endocrinology and Metabolism Aug, 87(8):3609-17.
Ellison, P.T., C.Panter-Brick, S.F. Lipson, and M.T. O’Rourke. 1993. the ecological context of human ovarian function. Human reproduction (:2248-58.
Ettinger, B., D.M.Black, B.H.Mitlak, R.K. Knickerbocker, et al. 1999. reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282:637-45.
Ettinger, B., H.K. Genant, and C.E. Cann. 1985. Long-term estrogen replacement therapy prevents bone loss and fractures. Annals of Internal Medicine 102:319- 24.
Felson, D.T., Y.Zhang, M.T. Hannan, D.P.Kiel, P.W.F.Willson, and J.J.Anderson. 1993. the effect of postmenopausal estrogen therapy on bone density in elderly women. New England Journal Of Medicine 329:1141-46.
Gordon, G.S., J. Picchi and B.S. Root. 1973. Anti-fracture efficacy of long-term
Hammond, C.B., F.R. Jelvsek, K.L. Lee, W.T. Creasman, and R.T.Parker. 1979. Effects of long-term estrogen replacement therapy. I. Metabolic effects. American Journal of Obstetrics and Gynecology 133:525-36.
Hedlund, L.R., and J.C.Gallagher. 1989. Increased incidence of hip fracture in osteoporotic women treated with sodium fluorid. J Bone and Miner Res 4:223-25.
Hosking, D., C.E. Chilvers, C. Christiansen, P.Ravn, et al. 1998. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. NEJM 19 February 1998, 338:485-92.
Hutchinson, T.A., S.M. Polansky, and A.R. Feinstein. 1979. Postmenopausal oestrogens protect against fractures of hip and distal radius: A case control study. Lancet II:705-709.
Israel, E., et al. 2001. Effects of inhaled glucocorticoids on bone density in premenopausal women. New England Journal of Medicine 345:941-47.
Jacobsen, S.J., J.Goldberg, T.P. Miles, J.A. Brody, et al. 1990. Regional variation in the incidence of hip fractures: US white women aged 65 years or older. JAMA 264:500-501.
Johansen, J., S.B.Jensen, B.J. Riis, et al. 1990. Bone formation is stimulated by combined estrogen, progestagen. Metabolism 39:1122-26.
Kass-Wolff, J.H. 2001. Bone loss in adolescents using Depo-Provera. Journal of Society of Pediatric Nursing Jan-Mar 6(1):21-31.
Kleerekoper, M.E., E. Peterson, E.Phillips, D. Nelson, et al. 1989. Continuos sodium fluoride therapy does not reduce vertebral fracture rate in postmenopausal osteoporosis (abstract). J Bone and Miner res 4 (Suppl.1.):S376.
Lee, J.R. 1990. Osteoporosis reversal: The role of progesterone. Intern Clin Nutr Rev 10:384-91.
1990 Osteoporosis reversal with transdermal progesterone (letter). Lancet 336:1327.
1991 Is natural progesterone the missing link in osteoporosis prevention and treatment? Medical Hypothesis 35:316-318.
Lees, B., T.Molleson, T.R.Arnett, and J.C. Stevenson. 1993. Differences in
Lees, C.J., T.C. Register, et al. 2002. Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause Sep-Oct, 9(5):320-28.
Lindsay R., D.M.Hart, C.Forrest, and C. Baird. 1980. Prevention of spinal osteoporosis in oophorectomized women. Lancet II:1151-54.
Manolagas, S.C., R.L.Jilka, G.Hangoc, et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91.-
Munk-Jensen,N., S.P. Nielsen, E.B. Obel, and P.B. Eriksen. 1988. Reversal of postmenopausal vertebral bone loss by oestrogen and progestagen: A double- blind placebo-controlled study. British Medical Journal 296:1150-52.
Osteoporosis prevention, diagnosis, and therapy. 2001. NIH Consensus Conference Report. JAMA 285:785-95
Prior, J.C. 1990. Progesterone as a bone-trophic hormone. Endocrine Reviews 11:386-98.
Prior J.C., and Y.M. Vigna. 1990. Spinal bone loss and ovulatory disturbances. New England Journal of Medicine 223:1221-27.
Prior J.C., Y.M. Vigna and N. Alojado. 1991. Progesterone and the prevention of osteoporosis. Canadian Journal of Obstetrics/Gynecology and Women’s Health Care 3:178-84.
Prior J.C., Y.M. Vigna and R. Burgess. Medroxyprogesterone acetate increases trabecular bone density in women with menstrual disorder. Presented at the annual meeting of the Endocrine Society, Indianapolis, June 11, 1987
Riggs, B.L., S.F.Hodgson, W.M. O’Fallon, E.Y.S. Chao, et al. 1990. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine 322:802-809.
Riggs, B.L., H.W. Wahner, L.J.Melton, et al. 1986. Rates of bone loss in the appendicular and axial skeleton of women: evidence of substantial vertrebal bone loss before menopause. J Clin Invest 77:1487-91.
Rudy, D.R. 1990. Hormone replacement therapy. Postgraduate Medicine Dec,
Schmidt, I.U., G.K. Wakely, et al. 2000. Effects of estrogen and progesterone on tibia histomorphometry in growing rats. Calcif Tissues Int 67(1):47-52.
Siris, E., et al. 2002. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Osteoporosis International Nov. 13(11):907-13.
Sowers, M. F.R., M.K. Clark, M.L. Jannausch, and R.B. Wallace.1991. A prospective study of bone mineral content and fracture in communities with differential fluoride exposure. American Journal Of Epidemiology 134:649-60.
Vieth, Reinhold. 1999 Vitamin D Supplementation, 25-hydroxy-vitamin D concentrations and safety. American Journal of Clinical Nutrition, vol. 69. no. 5, 842-856.
Weiss, N.S., C.L. Ure, J.H. Ballard, A.R. Williams, and J.R. Daling. 1980. Decreased risk of fracture of hip and lower forearm with postmenopausal use of estrogen. New England Journal of Medicine. 303:1195-98.
Barbagallo, M., L.J. Dominguez, at al. 2001. vascular effects of progesterone: role of cellular calcium regulation. Hypertension 37:142-47.
Cheng, W., O.D. Lau, et al. 1999. Two antiatherogenic effects of progesterone on human macrophages: Inhibition of cholesterol ester synthesis and block of its enhancement by gluco-corticoids. Journal of Clinical Endocrinology and metabolism 64:265-71.
ESPRIT team. 2002. Oestrogen therapy for prevention of re-infraction in postmenopausal women: a randomized placebo controlled trial. Lancet 360:2001- 2008.
Herrington, D.., D.M. Reboussin, et al. 2000. Effects of estrogen replacement on the progression of coronary-artery artherosclerosis. NEJM 343:522-37.
Huley, S., D. Grady, T. Bush, C. Furberg, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA August 19, 280:605-613.
Miyagawa, K., J. Rosch, J.F. Stanczyk, and K. Hermsmeyer. 1997. Medroxyprogesterone acetate interferes with ovarian steroid protection against coronary vasospasm. Nature Medicine 3:324-27.
Moura, M.J., and F.K. Marcondes. 2001. Influence of estradiol and progesterone on the sensitivity of rat thoractic aorta to non-adrenaline. Life Sciences 68:881-88.
Otsuki M., and H.. Saito. 2001. progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human endothelial cells. Arteriosclerosis Thrombosis Vascular Biology 21:243-48.
Prior, J.C. 1992. Letter. New England Journal of Medicine 326:705-706.
Ray, W.A., C.M. Stein, et al. 2002. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 359:118-23.
Rodriguez, I., M.J. Kilborn, et al. 2001. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 1322-26.
Rossouw, J.E. 2002. Commentary: Hormones for coronary disease-full circle. Lancet 360:1996-97.
Stampfer, M.J., G.A. Colditz, W.C. Willett, et al. 1991. Postmenopausal estrogen therapy and cardiovascular disease-10 year follow up from the Nurses’ Questionnaire Study. New England Journal of Medicine 325:756-62.
Tribble, D.L., and E. Frank. 1994. Dietary antioxidants, cancer, and atherosclerotic heart disease. W J Med 161:605-12.
Wilson, P,W.F., R.J.Garrison, and W.P. Castelli. 1985. Post-menopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. New England Journal of Medicine 313:1038-43.
Writing Group for the WHI Investigation. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 17 July 2002, 288:321- 333.
A report by Ruby Senie, PhD, of the Centers for Disease Control, at the annual science writers seminar sponsored by the American Cancer Society. Reported by the Feb 5, 1992, issue of Health and by the May 7, 1992, issue of Medical
Astrow, Alan B., M.D. 1994. Rethinking cancer (letter). Lancet, Feb 26.
Bergkvist, L., H-O. Adami, I. Persson, R. Hoover, and C. Schairer. 1989. the risk of breast cancer after estrogen and estrogen-progestin replacement. New England Journal of Medicine 321:293-97.
Campbell, B.C., and P.T. Ellison. 1992. Menstrual variation in salivary testosterone among regularly cycling women. Horm Res (Switzerland) 37(4-5): 132-36.
2002 The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern med Sep 3, 137 (5 part 1.): 305-12.
Cauley, J.A. 1999. Elevated serum estradiol and testosterone concentration associated with a high risk for breast cancer: Study of Osteoporotic Fractures Research Group. Ann Intern Med Feb 16, 130 (4 Pt 1):270-77.
Chang, K.J.., et al. 1995. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 63:785-91.
Cowan, L.D., L. Gordis, J.A. Tonascia, and G.S. Jones. 1981. Breast cancer incidence in women with a history of progesterone deficiency. American Journal of Epidemiology 114:209-17.
Ellison, P.T. 1993. Measurements of salivary progesterone. Annals of the New York Academy of Science Sept 20, 694:161-76.
Ellison, P.T., S.F. Lipson, M.T. O’Rourke, et al. 1993. Population variation in ovarian function (Letter) Lancet Aug 14, 342:433-34.
Ellison, P.T., C. Panter-Brick, S.F. Lipson, and M.T. O’Rourke. 1993. The Ecological Context of Human Ovarian Function. Human Reproduction 8(12):2248-58.
Foidart, J.M., C. Colin, et al. 1998. Estradiol and progesterone regulate the proliferation of the human breast epithelial cells. Fertility and Sterility May, 69(5):963-69.
Gruenigen, V.E., and J.R. Karlen. 1995. Carcinoma of the endometrium.
Henderson, B.E., R.K. Ross, M.C. Pike, and J.T. casagrande. 1982. Endogenous hormones as a major factor in human cancer. Cancer Research 42:3232-39.
Hoover, R., L.A. Gray, Sr., P. Cole, and B. MacMahon. 1976. Menopausal estrogens and breast cancer. New England Journal of Medicine 295:401-405.
Hiatt, R.A., R. Bawol, G.D. Friedman, and R. Hoover. 1984. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 54:139-44.
Kerlikowske, K., D. Grady, S.M. Rubin, et al. 1995. Efficacy of screening mammography. JAMA 273:149-54.
La Vecchia, C., A. Decarli, F. Parazzini, A. Gentile, C. Liberati, and S. Franceschi. 1986. Noncontraceptive oestrogens and the risk of breast cancer in women. International Journal of Cancer 38:853-58.
Malet, C., P. Spitzer, et al. 2000. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture. Journal of Steroid Biochemistry and Molecular Biology, vol. 73, issue ¾, 171-181.
Miller, A.B., C.J.Baines, and T.Wall. 1992. Canadian national breast screening study 2: Breast cancer detection and death rates among women aged 50 to 59 years. Canadian Medical Association Journal 147:1477-88.
Pike, M.C., D.V. Spicer, L.Dahmoush, and M.F. Press. 1993. Estrogens, progestogens, normal breast proliferation, and breast cancer risk. Epidem Rev 15:64-82.
Raloff, Janet. 1993. Ecocancers. Do environmental factors underlie a breast cancer epidemic? Science News, July 3, 144:10-13.
Willett, W.C., M.J. Stampfer, M.B. Colditz, et al. 1987. Dietary fat and the risk of breast cancer. New England Journal of Medicine 316:22-28.
Bodner K., and B. Bodner-Adler. 2003. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res Jan-Feb, 23(1B):729-32.
Crane, M.G., and J.J. Harris. Effects of gonadal hormones on plasma rennin activity and aldosterone excretion rate. In H.A. Salhanick, D.M. Kipnis and R.L. Vande Weile, eds. Metabolic Effects of Gonadal Hormones and Contraceptive Steroids. New York: Plenum Press, 1969:446-63, and discussion:736.
Crane, M.G., and J.J. Harris, and W. Widsor III. 1971. Hypertension, oral contraceptive agents and conjugated estrogens. Annals of Internal Medicine 74:13-21.
Dalton, K. The Premenstrual Syndrome and Progesterone Therapy. Chicago: Year Book medical Publishers, Inc., 1977.
DeBold, J.F., and C.A.Frye. 1994. Progesterone and the neural mechanisms of hamster sexual behavior. Psychoneuroendocrinology 19:563-79.
De Leo, V., G. Morgante, et al. 2002. A benefit-risk assessment of medical treatment for uterine leiomyomas. Drug Safety 25(11):759-79.
Eisinger, S.H., S. Meldrum, et al. 2003. Low-dose mifeprostone for uterine leiomyomata. Obstetrics and Gynecology Feb., 101(2):243-50.
Harris, B., L. Lovett, et al. 1994. Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study II. British Medical Journal Apr: 308:949-953.
Hodges, L.C., D.S. Hunter, et al. 2001. An in vivo/in vitro model to assess endocrine disrupting activity of xeno-estrogens in uterine leiomyoma. Annals of New York Academy of Sciences Dec:948:100-11.
Jeffries, Williams M.D. The Safe Uses of Cortisone. Springfield, IL: Charles C Thomas Publisher, 1981.
Kurachi, O., and H. Matsuo. 2001. Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone. Journal of Clinical Endocrinology and Metabolism. May: 86(5):2275-80.
Shozu, M., K. Murakami, et al. 2003. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroid aromatase inhibitor. Fertility and Sterility Ma, 79(3):628-31.
Smith, E.P., J. Boyd, G.R. Frank, et al. 1994. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. New England Journal of
Stampfer, M.J., G.A. Colditz, W.C. Willett, et al. 1991. Post-menopausal estrogen therapy and cardiovascular disease. New England Journal of Medicine 325:756- 62.
Walker, C.L. 2002. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res 57:277-94.
Witt, D.M., L.J. Young, and D. Crews. 1994. Progesterone and sexual behaviour in males. Psychoneuroendocrinology 19:553-62.
Diaz-Zagoya, J.C., J. Laguna, and J. Guzman-Garcia. 1971. Studies on the regulation of cholesterol metabolism by the use of structural analogue, diosgenin. Biochem Phamacol 20(12):3473-80.
Juarez-Oropeza, M. A., J.C. Diaz-Zagoya, and J.L. Rabinowitz. 1987. In vivo and in vitro studies of hypocholersterolemic effects of diosgenin in rats. International Journal of Biochemistry 19(8):679-83.
Melillo, Mark: 1994. Estrogen use may predispose women to lupus. Medical Tribune, November 17.
Odumosu, A. 1982. How vitamin C. clofibrate and diosgenin control cholesterol metabolism in male guinea-pigs. Int J Vitam Nutr Res Suppl (Switzerland) 23:187- 95.
Tuppala, M., U. Bjorses, T. Wahlstrom, and O. Ylikorkala. 1991. Luteal phase defect in habitual abortion: progesterone in saliva. Fertile Steril 56:41-44.
Anasti, J.N., H.B. Leonetti, and K. J. Wilson. 2001. Topical progesterone cream has anti-proliferative effect on estrogen-stimulated endometrium. Obstetrics and Gynecology 97:510.
Beumont, P.J.L., et al. 1972. Lutenizing hormone and progesterone levels after
Bourgain, C., et al. 1990. Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum Repod 5:537-43.
Chakmakjian, Z.R., and N.Y. Zackariah. 1987. Bioavailability of progesterone with different modes of administration. Journal of Reproductive medicine 32:443- 48.
Chang, K.J., T.T.Y. Lee, G.Linares-Cruz, S. Fournier, and B. de Lignieres. 1995. Influences of precutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 63:785-79.
Dabbs, J. 1990. Salivary testosterone measurements: reliability across hours, days and weeks. Phys behave 48:83-86-
De Lignieres, B.L. Dennerstein, and T. Backstorm. 1995. Influence of route of administration on progesterone metabolism. Maturitas Apr, 21(3): 251-57.
Devenuto, F., et al. 1969. Human erythrocyte membrane. Uptake of progesterone and chemical alterations. Biochim Biophys Acta 193:36-47.
Dollbaum, C.M., and G.F. Duwe. Absorption of progesterone after topical applications: serum and saliva levels. Presented at the 7th Annual Meeting of the American Menopause Society.
Foidart J.M., C.Colin, X.Denoo, and J. Desroux, et al. 1998. Estradiol and progesterone regulate proliferationof human breast epithelial cell. Fertility and Sterility 69:963-69.
Johnson, M.E, et al. 1995. Permeation of steroids through human skin. Journal of Pharmaceutical Science 84:1144-46.
Koefoed, P., and J. Brahm. 1994. the permeability of the human red cell membrane to steroid sex hormones. Biochim Biophys Acta 1195:55-62.
Leonetti, H.B., S. Longo, and J.N.Anasti. 1999. Transdermal progesterone cream for vasomotor symptoms and post-menopausal bone loss. Obstetrics and Gynecology 94:225-28.
Levine, H. and N. Watson. 2000. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus prometrium administered orally in
Nahoul, K., and D. de Ziegler 1993. Validity of serum progesterone levels after oral progesterone. Fertile Steril Jul, 60(1): 26-33.
O’Learly P., P. Feddema, K. Chan, et al. 2000. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. Clinical Endocrinology 53:615-20.
Waddell B.J., and P.C. O’Learly. 2002. Distribution and metabolism of topically applied progesterone in a rat model. Journal of Steroid Biochemistry and Molecular Biology 80:449-55.
Wren, B.G., K. McFarland, L.Edwards, et al. 2000. Effects of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone levels in post-menopausal women. Climateric 3:155-60.
Altura BM, Altura BT, “Magnesium and cardiovascular biology: An important link between cardiovascular risk factors and atherogenesis,” Cell Mol Biol Res 1995; 41(5):347- 59.
The American Heart Association, “Cardiovascular Disease in Women: A Statement for Healthcare Professionals from the American Heart Association, and “Women, Heart Disease and Stroke Statistics,” www.americanheart.org
Cerqueira MD, “Diagnostic testing strategies for coronary artery disease: special issues related to gender,” Am J Cardiol 1995;75:52D-60D.
Douglas PS, et al, “The evaluation of chest pain in women,” N Engl J Med 1996;344:1311-1315.
Fried LP, Kronmal RA, Newman AB, Bild DE, et al, “Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study,” JAMA 1998;279:585- 592.
Gatto L, et al, “Ascorbic acid induces a favourable lipoprotein profile in women,” J Am Coll Nutr 1996; 15(2): 154-58.
Kannel WB, “Natural history of angina pectoris in the Framingham Study: prognosis and survival. Am J Cardiol 1972;29:154-163.
Kung S, et al, “Are there gender differences regarding coronary artery
La Croix AZ, et al, “Health aging. A women’s issue,” West J Med 1997; 167(4):220-32.
Lauer MS, et al, “Sex and Diagnostic Evaluation of Possible Coronary Artery Disease After Exercise Treadmill Testing at One Academic Teaching Center,” Am Heart J 1997;134(5):807-813.
Matthews, K, et al, “Prior to use of estrogen replacement therapy, are users healthier than non-users?” Am J Epidemiol 1996; 143(10):971-8.
Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P, “Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease,” Lancet 1993; 342:133-136.
Sidney S, et al, “Myocardial Infarction and the Use of Estrogen and Estrogen- Progestogen in Postmenopausal Women,” Ann Int Med 1997; 127:501-508.
Stephens N, Parsons A, et al, “Randomised controlled trial of Vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS),” Lancet 1996; 347:781- 86.
Verhoef P, Stampfer M, et al, “Homocysteine metabolism and risk of myocardial infarction: Relation with Vitamins B6, B12 and folate,” Am J Epidemiol 1996;143;845-59.
3rd International Symposium, Women’s Health and Menopause, Florence, Italy, June 13-16, 1998, Fondazione Giovanni Lorenzini Medical Science Foundation, Via Appiani, 7, 20121 Milan, Italy.
Hermsmeyer K, Miyagawa K, Kelley ST, Rosch J, Hall AS, Axthelm MK, and Greenberg B, “Reactivity based coronary vasospasm independent of atherosclerosis in rhesus monkeys,” J Am Col Cardiol, 29:671-680, 1997.
Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K, “Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm, Nature Medicine, 3:324-327, 1997.
Miyagawa K, Vidgoff J, Hermsmeyer K, “Ca2+ release mechanism of primate reactivity based coronary vasospasm,” Am J Physiol, 272:H2645-H2654, 1997.
Minshall RD, et al “Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys,” J Clin Endoc Metabol, 83:649-659, 1998.
Minshall RD, Miyagawa K, Chadwick CC, Novy MJ, Hermsmeyer K, “In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones,” FASEB J, in press, August 1998.
Rodriques C, Calle EE, Loates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. American J Eidemiology 141: 828-834, 1995.
Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. 94:10937-10942, 1997.
Dollbaum CM, Duwe GF. Absorption of progesterone after topical applications: serum and saliva levels. Presented at the 7th Annual Meeting of the American Menopause Society.
Johnson ME, et al. Permeation of steroids through human skin. J Pharmaceutical Sci 84: 1144-1146, 1995.
Devenuto F, et al. Human erythrocyte membrane. Uptake of progesterone and chemical alterations. Biochim Biophys Acta 193: 36-47, 1969.
Koefoed P, Brahm J. The permeability of the human red cell membrane to steroid sex hormones. Biochim Biophys Acta 1195: 55-62, 1994.
Chang K-J, Lee TTY, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 63: 785-791, 1995.
(For those who wish to acquire an overview of the apoptosis matter that will be covered in the next issue, I recommend reading the article “To Die or Not to Die” in the January 28, 1998, issue of the JAMA.) (References are listed in order of mention in article.)
Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiology 1981;114:209-217.
Zava, David, Personal communication, as yet unpublished. Details coming in future issues.
Hrushesky WJM. Breast cancer, timing of surgery, and the menstrual cycle: Call for prospective trial. J Women’s Health 1996;5:555-566. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. British J Cancer 1996;73:1552-1555.
Chang K-J, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 1995;63:785-791.
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, et al., Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc.
Natl. Acad. Sci. 1997;94:10937-10942.
Chang K-J, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 1995;63:785-791.
Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiology 1981;114:209-217.
Darcy KM, Shoemaker SF, Lee PH, Ganis BA, and Margot M. Hydrocortisone and progesterone regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J Cellular Physiology 1995;163:365-379.
Formby B and Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effect on expression of p53 and Bcl-2. Sansum Medical Research Foundation, Santa Barbara, CA. Awaiting publication.
Gompel A, Malet C, Spritzer P, La Lardrie J-P, et al. Progestin effect on cell proliferation and 17*-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clinical Endocrinology and Metabolism 1986;63:1174.
Gompel A, Sabourin JC, Martin A, Yaneva H, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathology 1994;144:1196-1202.
Hrushesky WJM. Breast cancer, timing of surgery, and the menstrual cycle: Call for prospective trial. J Women’s Health 1996;5:555-566.
Inoh A, Kamiya K, Fujii Y, and Yokoro K. Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn J Cancer Res 1985; 76:699-704.
Kandouz M, Siromachkova M, Jacob D, Marquet BC, et al. Antagonism between estradiol and progestin on Bcl-2 expression in breast cancer cells. Int. J. Cancer 1996;68:120-125.
Leis HP. Endocrine prophylaxis of breast cancer with cyclic estrogen and progesterone. Inern Surg 1966;45:496-503.
Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. British J Cancer 1996;73:1552-1555.
Pujol P, Hilsenbeck SG, Chamness GC, and Elledge RM. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 1994;74:1601-1606.
Rodriquez C, Calle EE, Coates RJ, Miracle-McMahill HL, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiology 1995;141:828- 835.
Sabourin JC, Martin A, Baruch J, Truc JB, et al. Bcl-2 expression in normal breast tissue during the menstrual cycle. Int. J. Cancer 1994;59:1-6.
Shi-Zhong Bu, De-Ling Yin, Xiu-Hai Ren, Li-Zhen Jiang, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian
Weinberg RA. How cancer arises. Scientific American, September 1996;pgs 62- 70.
(These references appear in the approximate order they were referred to in the interview.)
Liener IE, Implications of antinutritional components in soybean foods.Crit Rev Food Sci Nutr. 34: 31-67, 1994.
Businco L, et al. Allergenicity and nutritional adequacy of soy protein formulas. J Pediatr 121: S21-S28, 1992.
Wilgus HS Jr. et al. Goitrogenicity of soybeans. J Nutr 22: 43-52, 1941.
Fallon SW, Enig MG. Soy products for dairy products? Not so fast.. Health Freedom News, September, 1995.
Ferguson EL, et al. Dietary calcium, phytate, and zinc intakes and the calcium, phytate, and zinc molar ratios of the diets of a selected group of East African children. Am J Clin Nutr 50(6):1450-1456, 1989.
Sandberg AS. The effect of food processing on phytate hydrolysis and availability of iron and zinc. Adv Exp Med Biol 289:499-508, 1991.
Davies NT, et al. An evaluation of the phytate, zinc, copper, iron and manganese contents of, and zn availability from, soya-based textured-vegetable-protein meat- substitutes or meat-extenders. Br J Nutr 41(3):579-589, 1979.
Ferguson EL, et al. The zinc nutriture of preschool children living in two African countries. J Nutr 123:1487-1496, 1993.
Sandstrom B, et al. Absorption of zinc from soy protein meals in humans. J Nutr 117:321-327, 1987.
Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutrition and Cancer 27: 31-40, 1997.
Anderson RL, et al. Compositional changes in trypsin ihibitors, phytic acid, saponins and isoflavones related to soybean processing. J Nutr 125: 581S-588S, 1995.
Burke GL. The potential use of a dietary soy supplement as a post-menopausal hormone replacement therapy. Second International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, Brussells, Belgium, Oral Abstract, 1996.
Fotsis T. Genistein, a dietary-derived inhibitor or in vitro angiogenesis. Proc Natl Acad Sci 90: 2690-2694, 1993.
Vera JC, et al. Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. J Biol Chem 271: 8719-8724, 1996.
Petrakis NL et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 5: 785- 794, 1996.
Santell RC, et al. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997 Feb;127(2):263-269.
Wang, C, et al. “Lignans and Isoflavonoids Inhibit Aromatase Enzyme in Human Preadipocytes.” J Steroid Biochem Mol Biol 50, 205-212, 1994.
Makela, S, et al. Estrogen-specific 17 -hydroxysteroid Oxidoreductase Type I as a Possible Target for the Action of Phytoestrogens. Proc Soc Exp Biol Med 208, 51-59, 1995.
Hoffmann R, et al. Interleukin-1beta-induced inhibition of hair growth in vitro is mediated by cyclic AMP. J Invest Dermatol 1997 Jan;108(1):40-42. DTZ: shows genistein inhibits hair growth by 60%.
Kruse FE, et al. Inhibition of neovascularization of the eye by dietary factors exemplified by isoflavonoids. Ophthalmologe 1997 Feb;94(2):152-156.
Ikeda Y, et al. GABAA receptor stimulation promotes survival of embryonic rat striatal neurons in culture. Brain Res Dev Brain Res 1997 Feb 20;98(2):253-258.
Wan Q, et al. Modulation of GABAA receptor function by tyrosine phosphorylation of beta subunits. J Neurosci 1997 Jul 1;17(13):5062-5069.
Christiansen, C, Riis BJ, Nilas L, Rodbro P, “Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis,” Lancet 12 October 1985:800-801.
Cummings SR, Mevitt MC, Browner WS et al for the Study of Osteoporotic Fractures Research Group, “Risk Factors for Hip Fracture in White Women,” N Engl J Med 1995;332:767-73.
Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Br art G, for the EPIDOS Group, “Fall-related factors and risk of hip fracture: the EPIDOS prospective study,” Lancet 1996; 348: 145-49.
Dempster DW, Lindsay R, “Pathogenesis of osteoporosis,” Lancet 1993; 341:797- 801.
Hoskins D, Chilvers CED, et al, “Prevention of bone loss with alendronate iin postmenopausal women under 60 years of age,” NEJM 1998; 338:485-492.
Ojasoo T, “Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data,” J Steroid Biochem Molec Biol 1994; 48:31-46.
Prior JC, “Progesterone as a Bone-Trophic Hormone,” Endocrine Reviews 1990; 11:386-398.
The Lancet 11 July 1998; 352: 80-81, 93-97, 98-101, Editorial by Kathleen I. Pritchard, U. of Toronto, Ontario.
Powles T, Eeles R, Ashley S, Easton D, et al, “Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial,” Lancet 1998; 352: 98-101.
Veronesi U, Maisonneuve P, Costa A, Sacchini V, et al, “Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women,” Lancet 1998;352:93-97.
Cummings SR, et al, “Endogenous hormones and the risk of hip and vertebral fractures among older women,” NEJM, 10 Sept 1998; 339: 733-738.
Hulley S, et al, “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women,” JAMA, 19 August 1998; 280: 605-613.
Prior JC, “Perimenopause: the complex endocrinology of the menopausal transition,” Endocrine Reviews 1998; 19(4):397-426.
Umekita, Yoshihisa et al, “Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride,” Proceedings of the National Academy of Science, Vol. 93, Issue 21, 11802-11807, October 15, 1996.
Bruchovsky, N, “The metabolism of testosterone and dihydrotestosterone in an androgen-dependent tumour. A possible correlation between dihydrotestosterone and tumour growth in vivo,” Biochem J, 1972 Apr;127(3):561-75.
Russell, Pamela, et al, “Growth factor involvement in progression of prostate cancer,” Clinical Chemistry, 1998;44:705-723.
Veldscholte J, “Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids,” Biochem Biophys Acta 1990 Apr 9;1052(1):187-94.
Brinton LA, et al, “Oral contraceptives and breast cancer risk among younger women,” J Natl Cancer Inst 1995 Jun 7;87(11):827-835.
Herman-Giddens ME, et al, “Secondary sexual characteristics and menses in young girls seen in office practiceSigma” Pediatrics 99: 505-512, 1997.
Li CI, Malone KE, et al “Age when maximum height is reached as a risk factor for breast cancer among young U.S. women,” Epidemiology 8: 559-565, 1997.
Paul C, Skegg DC, Spears GF, “Depot medroxyprogesterone (DepoProvera) and risk of breast cancer,” BMJ 1989 Sep 23;299(6702):759-762.
Rookus MA, van Leeuwen FE, “Oral contraceptives and risk of breast cancer in women aged 2054 years,” Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 1994 Sep 24;344(8926):844-851.
Olsson H, Borg A, et al, “A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer,” Med Oncol Tumor Pharmacother 1986;3(2):77-81.
Olsson H, et al, “Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age,” Anticancer Res 1987 Jul;7(4B):853-856.
Olsson H, “Oral contraceptive use and premenopausal breast cancer–a review of studies performed in southern Sweden,” Cancer Detect Prev 1991;15(4):265271.
Amikor meglátogatja a webhelyünket, itt tárolhatja vagy lekérheti az információkat a böngészőben, főként sütik formájában. Itt irányíthatja a személyes cookie-szolgáltatásait.